Phase II study of first-line combined chemotherapy bevacizumab with modified RPMI regimen for elderly or frail patients with unresectable or metastatic colorectal cancer (OGSG0802).
Shigeyoshi Iwamoto
No relevant relationships to disclose
Takeshi Kato
No relevant relationships to disclose
Motoki Yoshida
No relevant relationships to disclose
Yasuhiro Miyake
No relevant relationships to disclose
Masato Nakamura
No relevant relationships to disclose
Taroh Satoh
No relevant relationships to disclose
Daisuke Sakai
No relevant relationships to disclose
Masaki Matsuoka
No relevant relationships to disclose
Toshio Otsuji
No relevant relationships to disclose
Hiroshi Furukawa
No relevant relationships to disclose